Search research articles
Contact Us
Filters
Showing results (21-30 of 63) with videos related to
Page
of 7
Sort By:
Plos One
|
November 18, 2014
The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML
Guerry J Cook, David L Caudell, Howard L Elford, et al.
Biochemical and Biophysical Research Communications
|
July 2, 1998
Trimidox-mediated morphological changes during erythroid differentiation is associated with the stimulation of hemoglobin and F-cell production in human K562 cells
E W Iyamu, S E Adunyah, H L Elford, et al.
Molecular Cancer Therapeutics
|
February 4, 2021
Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer
Elizabeth A Wilson, Nahid Sultana, Khyati N Shah, et al.
Life Sciences
|
January 1, 1997
Iron binding capacity of didox (3,4-dihydroxybenzohydroxamic acid) and amidox (3,4-dihydroxybenzamidoxime) new inhibitors of the enzyme ribonucleotide reductase
M Fritzer-Szekeres, L Novotny, A Vachalkova, et al.
Molecular Cancer Therapeutics
|
September 4, 2015
Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer
Khyati N Shah, Elizabeth A Wilson, Ritu Malla, et al.
Advances in Experimental Medicine and Biology
|
May 23, 1998
Iron binding capacity of didox (3,4 dihydroxybenzohydroxamic acid) and amidox (3,4 dihydroxybenzamidoxime) two inhibitors of the enzyme ribonucleotide reductase
M Fritzer-Szekeres, L Novotny, A Vachalkova, et al.
Blood Cells, Molecules & Diseases
|
November 27, 1999
A combination of hydroxyurea and isobutyramide to induce fetal hemoglobin in transgenic mice is more hematotoxic than the individual agents
A M Buller, H L Elford, C C DuBois, et al.
Cancer Research
|
December 1, 1977
Effect of methotrexate and 5-fluorodeoxyuridine on ribonucleotide reductase activity in mammalian cells
H L Elford, E L Bonner, B H Kerr, et al.
Antiviral Chemistry & Chemotherapy
|
March 13, 2003
Short-term treatment with novel ribonucleotide reductase inhibitors Trimidox and Didox reverses late-stage murine retrovirus-induced lymphoproliferative disease with less bone marrow toxicity than hydroxyurea
C N Mayhew, J D Phillips, M L Cibull, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
July 9, 2008
Apolipoprotein E-mediated immune regulation in sepsis
Omar M Kattan, F Behzad Kasravi, Erica L Elford, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 63) with videos related to
Sort By:
Page
of 7
Plos One
|
November 18, 2014
The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML
Guerry J Cook, David L Caudell, Howard L Elford, et al.
Biochemical and Biophysical Research Communications
|
July 2, 1998
Trimidox-mediated morphological changes during erythroid differentiation is associated with the stimulation of hemoglobin and F-cell production in human K562 cells
E W Iyamu, S E Adunyah, H L Elford, et al.
Molecular Cancer Therapeutics
|
February 4, 2021
Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer
Elizabeth A Wilson, Nahid Sultana, Khyati N Shah, et al.
Life Sciences
|
January 1, 1997
Iron binding capacity of didox (3,4-dihydroxybenzohydroxamic acid) and amidox (3,4-dihydroxybenzamidoxime) new inhibitors of the enzyme ribonucleotide reductase
M Fritzer-Szekeres, L Novotny, A Vachalkova, et al.
Molecular Cancer Therapeutics
|
September 4, 2015
Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer
Khyati N Shah, Elizabeth A Wilson, Ritu Malla, et al.
Advances in Experimental Medicine and Biology
|
May 23, 1998
Iron binding capacity of didox (3,4 dihydroxybenzohydroxamic acid) and amidox (3,4 dihydroxybenzamidoxime) two inhibitors of the enzyme ribonucleotide reductase
M Fritzer-Szekeres, L Novotny, A Vachalkova, et al.
Blood Cells, Molecules & Diseases
|
November 27, 1999
A combination of hydroxyurea and isobutyramide to induce fetal hemoglobin in transgenic mice is more hematotoxic than the individual agents
A M Buller, H L Elford, C C DuBois, et al.
Cancer Research
|
December 1, 1977
Effect of methotrexate and 5-fluorodeoxyuridine on ribonucleotide reductase activity in mammalian cells
H L Elford, E L Bonner, B H Kerr, et al.
Antiviral Chemistry & Chemotherapy
|
March 13, 2003
Short-term treatment with novel ribonucleotide reductase inhibitors Trimidox and Didox reverses late-stage murine retrovirus-induced lymphoproliferative disease with less bone marrow toxicity than hydroxyurea
C N Mayhew, J D Phillips, M L Cibull, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
July 9, 2008
Apolipoprotein E-mediated immune regulation in sepsis
Omar M Kattan, F Behzad Kasravi, Erica L Elford, et al.
Page
of 7